Acura Pharmaceuticals Inc (ACUR)
0.01
+0.01
(+257.14%)
USD |
OTCM |
Apr 19, 10:26
Acura Pharmaceuticals Research and Development Expense (Quarterly): 0.385M for Sept. 30, 2021
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2021 | 0.344M |
| September 30, 2021 | 0.385M |
| June 30, 2021 | 0.39M |
| March 31, 2021 | 0.405M |
| December 31, 2020 | 0.43M |
| September 30, 2020 | 0.519M |
| June 30, 2020 | 0.445M |
| March 31, 2020 | 0.387M |
| December 31, 2019 | 0.465M |
| September 30, 2019 | 0.465M |
| June 30, 2019 | 0.262M |
| March 31, 2019 | 0.313M |
| December 31, 2018 | 0.083M |
| September 30, 2018 | 0.549M |
| June 30, 2018 | 0.477M |
| March 31, 2018 | 0.65M |
| December 31, 2017 | 0.913M |
| September 30, 2017 | 1.077M |
| June 30, 2017 | 1.02M |
| March 31, 2017 | 0.711M |
| December 31, 2016 | 0.77M |
| September 30, 2016 | 0.841M |
| June 30, 2016 | 1.403M |
| March 31, 2016 | 1.014M |
| December 31, 2015 | 0.701M |
| Date | Value |
|---|---|
| September 30, 2015 | 0.432M |
| June 30, 2015 | 0.511M |
| March 31, 2015 | 0.964M |
| December 31, 2014 | 0.908M |
| September 30, 2014 | 0.955M |
| June 30, 2014 | 1.281M |
| March 31, 2014 | 1.438M |
| December 31, 2013 | 0.803M |
| September 30, 2013 | 1.289M |
| June 30, 2013 | 0.805M |
| March 31, 2013 | 2.026M |
| December 31, 2012 | 1.208M |
| September 30, 2012 | 0.696M |
| June 30, 2012 | 0.919M |
| March 31, 2012 | 0.903M |
| December 31, 2011 | 0.792M |
| September 30, 2011 | 0.962M |
| June 30, 2011 | 1.142M |
| March 31, 2011 | 1.141M |
| December 31, 2010 | 1.463M |
| September 30, 2010 | 1.142M |
| June 30, 2010 | 1.525M |
| March 31, 2010 | 3.047M |
| December 31, 2009 | 1.845M |
| September 30, 2009 | 1.494M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.262M
Minimum
Jun 2019
0.519M
Maximum
Sep 2020
0.4088M
Average
0.405M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 4.196M |
| Ampio Pharmaceuticals Inc | 1.242M |